PATH Inventprise Inc. Phase 1/2 Group B Streptococcus Investigational Vaccine Clinical Trial

Brief description of study

The purpose of this study is to gain understanding of the safety, tolerability, and immunogenicity of a new Group B streptococcus (GBS) investigational vaccine (IVT GBS-06) among women of childbearing age. Group B streptococcus (GBS) is a bacterium that can cause severe bacterial infections. About 1 in 5 women carry this bacterium, which can be transferred to their baby, resulting in a life-threatening infection and potentially invasive diseases such as sepsis, pneumonia, and meningitis. It is important to prevent GBS-related infections for those in vulnerable groups, especially among infants born to women carrying this bacterium.

There will be 4 study groups. If you are eligible and agree to participate, you will be randomly assigned to 1 of 4 groups:

  • Groups 1, 2, and 3 will receive a single injection of the IVT-GBS 06 investigational vaccine candidate (75% chance)
  • Group 4 will receive the placebo injection (25% chance)
If you decide to participate in this study, you would be asked to complete a minimum of 7 in-person study visits over a period of approximately 7 months. You may be reimbursed $110 per each in-person study visit completed.




If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.